At the end of 2023, the FDA approved Casgevy for sickle cell disease, its first approval for a therapeutic that used the genome editing tool clustered regulatory interspaced palindromic repeats ...

These days, in the era of personalised medicine, whenever researchers discover a new cancer drug they are expected to show exactly how it works and to prove that it is exerting its therapeutic effect ...

In a paper published on aBIOTECH, the authors investigated the off-target effects of ADAR-mediated RNA editing in rice ...

As a fast and easy-to-use gene-editing technique, CRISPR is one of the biggest discoveries in 21 st century medical science, and an important facilitator of gene therapy development. Several gene ...

In a new study published in the Clinical and Translational Medicine, the research group of Prof. Chen-Yu Zhang and Prof. Xi Chen at Nanjing University evaluated the on- and off-target effects of ...

In this Interview, NewsMedical speaks with Amy Landreman about NanoBRET® Technology and its role in cellular target engagement. Could you start by explaining the significance of understanding cellular ...

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...

The use of poly (ADP-ribose) polymerase (PARP) inhibitor therapy is standard care in the management of patients with various malignancies including ovarian, breast, prostate, and pancreatic cancers.

Researchers based at the University of Toronto (U of T) Leslie Dan Faculty of Pharmacy have developed a novel ionizable lipid nanoparticle (LNP), called iso-A11B5C1, that can deliver mRNA specifically ...